Patents by Inventor Edward Yin-Shiang Lin

Edward Yin-Shiang Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
    Patent number: 12319679
    Abstract: Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, m, n, and p are as defined herein.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: June 3, 2025
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20250171463
    Abstract: Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
    Type: Application
    Filed: February 23, 2023
    Publication date: May 29, 2025
    Inventors: Martin Himmelbauer, Felix Gonzalez Lopez de Turiso, Edward Yin Shiang Lin, Vatee Pattaropong, Zhili Xin, Teyu Chen, John Howard Jones, Nupur Bansal, Robert Gilfillan
  • EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20250161281
    Abstract: Provided are compounds of the Formula (I): (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
    Type: Application
    Filed: January 23, 2023
    Publication date: May 22, 2025
    Inventors: Felix Gonzalez Lopez de Turiso, Martin Himmelbauer, Zhili Xin, Nupur Bansal, TeYu Chen, John Howard Jones, Edward Yin Shiang Lin
  • EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20250152574
    Abstract: Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
    Type: Application
    Filed: February 13, 2023
    Publication date: May 15, 2025
    Inventors: Martin Himmelbauer, Felix Gonzalez Lopez de Turiso, John H. Jones, Edward Yin Shiang Lin, Robin Prince, Vatee Pattaropong, Zhili Xin, TeYu Chen, Nupur Bansal
  • O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
    Patent number: 12275728
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: April 15, 2025
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • BTK INHIBITORS
    Publication number: 20250090524
    Abstract: Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.
    Type: Application
    Filed: November 11, 2022
    Publication date: March 20, 2025
    Inventors: Brian T. Hopkins, BIn Ma, Jürgen Schulz, Marta Nevalainen, TeYu Chen, Robin J. Prince, Harold George Vandeveer, Issac Marx, Simone Sciaboba, Edward Yin Shiang Lin
  • O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
    Patent number: 12180205
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 31, 2024
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • BTK INHIBITORS
    Publication number: 20240327380
    Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.
    Type: Application
    Filed: August 5, 2021
    Publication date: October 3, 2024
    Applicant: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Isaac Marx, Jürgen Schulz, Harold George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Martin Himmelbauer, Vatee Pattaropong, John Howard Jones, Rab Gilfillan, Edward Yin Shiang Lin, Felix Gonzalez Lopez de Turiso, Bin Ma
  • O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
    Publication number: 20240308995
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS
    Publication number: 20240294524
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Application
    Filed: April 11, 2024
    Publication date: September 5, 2024
    Inventors: Joseph ARNDT, Timothy CHAN, Kevin GUCKIAN, Gnanasambandam KUMARAVEL, Wen-Cherng LEE, Edward Yin-Shiang LIN, Daniel SCOTT, Lihong SUN, Jermaine THOMAS, Kurt VAN VLOTEN, Deping WANG, Lei ZHANG, Daniel ERLANSON
  • NRF2 ACTIVATOR
    Publication number: 20240279197
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.
    Type: Application
    Filed: December 19, 2023
    Publication date: August 22, 2024
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS
    Publication number: 20240083900
    Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 14, 2024
    Applicant: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Isaac Marx, Jürgen Schulz, George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Martin Himmelbauer, Vatee Pattaropong, John Howard Jones, Edward Yin-Shiang Lin, Felix Gonzalez Lopez de Turiso, Thomas Purgett, Andrew George Capacci, Simone Sciabola
  • O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS
    Publication number: 20230117898
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y, Y2, R3 and R4 are defined herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: April 20, 2023
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS
    Publication number: 20230113598
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 13, 2023
    Inventors: Joseph ARNDT, Timothy Chan, Kevin Guckian, Gnanasambandam Kumaravel, Wen-Cheng Lee, Edward Yin-Shiang Lin, Daniel Scott, Lihong Sun, Jermaine Thomas, Kurt Van Vloten, Deping Wang, Lei Zhang, Daniel Erlanson
  • Tetrahydronaphthalene derivatives useful as Nrf2 activators
    Patent number: 11465963
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 11, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
    Patent number: 11459324
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 4, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • AZETIDINYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
    Publication number: 20220259197
    Abstract: Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical comositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, and Z are as defined herein.
    Type: Application
    Filed: March 6, 2020
    Publication date: August 18, 2022
    Applicant: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
    Publication number: 20220106305
    Abstract: Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, n and p are as defined herein.
    Type: Application
    Filed: February 3, 2020
    Publication date: April 7, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • NRF2 ACTIVATOR
    Publication number: 20220048884
    Abstract: Provided are compounds of Formula A or I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 17, 2022
    Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin Shiang Lin, Brian Stuart Lucas, Bin Ma
  • O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
    Publication number: 20220041586
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 10, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin